Hivid Disease Interactions
There are 3 disease interactions with Hivid (zalcitabine).
DdC (applies to Hivid) cardiomyopathy
Major Potential Hazard, Low plausibility. Applicable conditions: Congestive Heart Failure
The use of zalcitabine (ddC) has been associated rarely with cardiomyopathy and congestive heart failure in patients with AIDS. Therapy with ddC should be administered cautiously in patients with preexisting cardiomyopathy or a history of congestive heart failure.
References (1)
- (2001) "Product Information. HIVID (zalcitabine)." Roche Laboratories
NRTIs (applies to Hivid) bone marrow suppression
Major Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts
The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC) and stavudine (d4T), may infrequently cause bone marrow suppression at recommended dosages. Anemia, leukopenia, thrombocytopenia and neutropenia have been reported. Therapy with these agents should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias. Routine blood counts are recommended.
References (3)
- (2002) "Product Information. Videx (didanosine)." Bristol-Myers Squibb
- (2001) "Product Information. HIVID (zalcitabine)." Roche Laboratories
- (2001) "Product Information. Zerit (stavudine)." Bristol-Myers Squibb
NRTIs (applies to Hivid) peripheral neuropathy
Major Potential Hazard, High plausibility.
The nucleoside reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), and stavudine (d4T), may commonly cause dose-related peripheral neuropathy, particularly in patients with advanced HIV disease. Usually, the neuropathy resolves slowly following prompt discontinuation of therapy, but it can be irreversible. These agents should be administered cautiously to patients with a history of neuropathy and avoided in patients with existing polyneuropathy. Therapy may be reinstituted following resolution of symptoms in patients who have previously experienced neuropathy with these drugs, but reduced dosages are recommended.
References (12)
- LeLacheur SF, Simon GL (1991) "Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine." J Acquir Immune Defic Syndr, 4, p. 538-9
- Broder S, Yarchoan R (1990) "Dideoxycytidine: current clinical experience and future prospects." Am J Med, 88, s31-3
- Dubinsky RM, Yarchoan R, Dalakas M, Broder S (1989) "Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC)." Muscle Nerve, 12, p. 856-60
- Dubinsky RM, Dalakas M, Yarchoan R, Broder S (1988) "Follow-up of neuropathy from 2'3'-dideoxycytidine." Lancet, 1, p. 832
- Whittington R, Brogden RN (1992) "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs, 44, p. 656-83
- Matthews SJ, Cersosimo RJ, Spivack ML (1991) "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy, 11, p. 419-49
- (2002) "Product Information. Videx (didanosine)." Bristol-Myers Squibb
- (2001) "Product Information. HIVID (zalcitabine)." Roche Laboratories
- Martinez OP, French MA (1993) "Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathy." AIDS, 7, p. 901-2
- (2001) "Product Information. Zerit (stavudine)." Bristol-Myers Squibb
- Fichtenbaum CJ, Clifford DB, Powderly WG (1995) "Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection." J Acquir Immune Defic Syndr Hum Retrovirol, 10, p. 169-74
- Moore RD, Fortgang I, Keruly J, Chaisson RE (1996) "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med, 101, p. 34-40
Switch to consumer interaction data
Hivid drug interactions
There are 156 drug interactions with Hivid (zalcitabine).
Hivid alcohol/food interactions
There is 1 alcohol/food interaction with Hivid (zalcitabine).
Report options
More about Hivid (zalcitabine)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Biktarvy
Biktarvy is a complete HIV-1 treatment in a once-a-day single tablet containing three antiviral ...
Descovy
Descovy is used to treat and prevent HIV infection in adults and adolescents. When used for HIV-1 ...
Cabenuva
Cabenuva (cabotegravir and rilpivirine) injections are a long-acting HIV treatment used to keep HIV ...
Dovato
Dovato is used to treat HIV-1 infection in adults and children 12 years and older weighing at least ...
Truvada
Truvada is used to prevent HIV (HIV PrEP) or treat HIV-1 infection in combination with other HIV-1 ...
Atripla
Atripla prevents the human immunodeficiency virus (HIV) from reproducing in your body. Learn about ...
Complera
Complera (emtricitabine, rilpivirine, and tenofovir) is used to treat HIV infection. Includes ...
Stribild
Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) is used to treat HIV-1 infection ...
Epzicom
Epzicom is used to treat HIV, which causes the acquired immunodeficiency syndrome (AIDS). Learn ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
